drugset / Trial / NCT04753476

Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia

NCT04753476 ↗

RandomizedParallel-groupOpen-labelTreatment

Summary

In this randomized controlled trial (RCT), severe cases of COVID-19 infection will be treated with secretome of hypoxia-mesenchymal stem cells. The improvement in clinical, laboratory, and radiological manifestations will be evaluated in treated patients compared with the control group.

Timeline

Start
2020-06-08
Primary completion
2022-02-01
Completion
2022-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Secretome-MSCs Unknown 1 ml Intramuscular